RxSight, Inc. to Report First Quarter 2022 Financial Results on May 5, 2022
RxSight, Inc. (NASDAQ: RXST) will announce its Q1 2022 financial results on May 5, 2022, after market close. A conference call to discuss the results is scheduled for 1:30 PM PT / 4:30 PM ET the same day. Investors can access the call via the company's website or by phone. The company specializes in ophthalmic medical devices, particularly the Light Adjustable Lens (LAL), a unique intraocular lens technology that enhances post-cataract surgery vision. The LAL includes the new ActivShield™ technology for UV protection.
- The RxSight Light Adjustable Lens (LAL) technology is unique and offers customizable visual acuity.
- The introduction of ActivShield™ technology enhances the product's appeal due to added UV protection.
- None.
ALISO VIEJO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – April 21, 2022 – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that it will report financial results for the first quarter 2022 after the market close on Thursday, May 5, 2022. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.rxsight.com, on the Investors page in the News and Events section. The call will also be available by dialing 877-545-0523 (U.S.) or 973-528-0016 (International) five to ten minutes prior to the start time, using conference ID: 217735.
About RxSight, Inc.
RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The LAL now features ActivShield™ technology, a revolutionary UV protection layer built into the lens. Additional information about RxSight can be found at www.rxsight.com.
Investor Relations Contact:
Philip Taylor
Gilmartin Group
415.937.5406
IR@rxsight.com
Company Contact:
Shelley Thunen
Chief Financial Officer
IR@rxsight.com
FAQ
When will RxSight report its Q1 2022 financial results?
What is the significance of RxSight's Light Adjustable Lens?
How can investors access the Q1 2022 earnings call?
